Improving Diagnostic Methods for Mycobacterium tuberculosis

Tuberculosis remains a leading infectious disease killer, claiming 1.5 million lives annually. Traditional diagnostic methods suffer from poor sensitivity, lengthy turnaround times, and inability to detect drug resistance, creating critical gaps in TB detection and treatment monitoring. We analyzed five studies investigating novel TB diagnostic approaches: lipoarabinomannan (LAM) monitoring in urine, microRNA profiling in exhaled breath condensate, diagnostic accuracy comparison in subclinical versus active TB, molecular assay performance evaluation, and metagenomic sequencing for extrapulmonary TB. LAM monitoring revealed a biphasic treatment pattern, increasing from 35.0 to 48.0 pg/mL at day 13, then declining to near-zero by day 316, providing independent treatment response information. MicroRNA analysis achieved exceptional diagnostic performance (AUC: 0.971-1.0) for distinguishing TB patients from healthy controls. Subclinical TB showed consistently lower detection rates across microbiological methods (AFB: 11.6% vs 25.2%, Xpert: 40.6% vs 63.8%) but comparable IGRA performance (85.7% vs 84.1%), correlating with low bacterial loads. Molecular assays demonstrated variable performance with false-positive rates of 1.0-3.0% and false-negative rates of 0-11.0%. Metagenomic sequencing achieved superior extrapulmonary TB detection (mNGS: 89.47%, mTGS: 82.89%), with optimal performance when combining Xpert with mNGS (93.42% sensitivity, 100% specificity). Novel diagnostic approaches address critical TB detection gaps. LAM kinetics offer valuable treatment monitoring, microRNA signatures provide excellent diagnostic discrimination, and metagenomic sequencing shows promise for extrapulmonary cases. However, poor conventional method performance in subclinical TB highlights urgent needs for more sensitive approaches. Integration of multiple diagnostic modalities will be essential for clinical implementation in high-burden settings.